Michael Waterman
Faculty Member
Last active: 2/12/2015

VNI cures acute and chronic experimental Chagas disease.

Villalta F, Dobish MC, Nde PN, Kleshchenko YY, Hargrove TY, Johnson CA, Waterman MR, Johnston JN, Lepesheva GI
J Infect Dis. 2013 208 (3): 504-11

PMID: 23372180 · PMCID: PMC3698996 · DOI:10.1093/infdis/jit042

Chagas disease is a deadly infection caused by the protozoan parasite Trypanosoma cruzi. Afflicting approximately 8 million people in Latin America, Chagas disease is now becoming a serious global health problem proliferating beyond the traditional geographical borders, mainly because of human and vector migration. Because the disease is endemic in low-resource areas, industrial drug development has been lethargic. The chronic form remains incurable, there are no vaccines, and 2 existing drugs for the acute form are toxic and have low efficacy. Here we report the efficacy of a small molecule, VNI, including evidence of its effectiveness against chronic Chagas disease. VNI is a potent experimental inhibitor of T. cruzi sterol 14α-demethylase. Nontoxic and highly selective, VNI displays promising pharmacokinetics and administered orally to mice at 25 mg/kg for 30 days cures, with 100% cure rate and 100% survival, the acute and chronic T. cruzi infection.

MeSH Terms (13)

Administration, Oral Animals Chagas Disease Chronic Disease Disease Models, Animal Enzyme Inhibitors Female Imidazoles Mice Mice, Inbred BALB C Oxadiazoles Survival Analysis Treatment Outcome

Connections (1)

This publication is referenced by other Labnodes entities: